- Home
- MCHX vs GNLX Comparison
MCHX vs GNLX Comparison
Compare MCHX & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCHX
- GNLX
- Stock Information
- Founded
- MCHX 2003
- GNLX 2001
- Country
- MCHX United States
- GNLX United States
- Employees
- MCHX N/A
- GNLX N/A
- Industry
- MCHX Business Services
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- MCHX Consumer Discretionary
- GNLX Health Care
- Exchange
- MCHX Nasdaq
- GNLX Nasdaq
- Market Cap
- MCHX 84.3M
- GNLX 94.0M
- IPO Year
- MCHX 2004
- GNLX 2023
- Fundamental
- Price
- MCHX $1.90
- GNLX $2.53
- Analyst Decision
- MCHX
- GNLX Strong Buy
- Analyst Count
- MCHX 0
- GNLX 4
- Target Price
- MCHX N/A
- GNLX $17.75
- AVG Volume (30 Days)
- MCHX 43.2K
- GNLX 163.7K
- Earning Date
- MCHX 05-13-2025
- GNLX 05-06-2025
- Dividend Yield
- MCHX N/A
- GNLX N/A
- EPS Growth
- MCHX N/A
- GNLX N/A
- EPS
- MCHX N/A
- GNLX N/A
- Revenue
- MCHX $47,951,000.00
- GNLX N/A
- Revenue This Year
- MCHX $6.83
- GNLX N/A
- Revenue Next Year
- MCHX N/A
- GNLX N/A
- P/E Ratio
- MCHX N/A
- GNLX N/A
- Revenue Growth
- MCHX N/A
- GNLX N/A
- 52 Week Low
- MCHX $1.26
- GNLX $1.60
- 52 Week High
- MCHX $2.40
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- MCHX 66.93
- GNLX 48.27
- Support Level
- MCHX $1.54
- GNLX $2.38
- Resistance Level
- MCHX $1.74
- GNLX $2.60
- Average True Range (ATR)
- MCHX 0.13
- GNLX 0.19
- MACD
- MCHX 0.03
- GNLX 0.01
- Stochastic Oscillator
- MCHX 95.74
- GNLX 38.58
About MCHX Marchex Inc. Class B
Marchex Inc is a conversational analytics and solutions company that helps businesses connect, drive, measure, convert callers into customers, and connect the voice of the customer to their business. It delivers data insights and incorporates artificial intelligence (AI)-powered functionality that drives insights and solutions to help companies find, engage, and support their customers across voice and text-based communication channels. The group enables sales and marketing teams to deliver the buying experiences that today's customers expect. The company generates the majority of its revenues from core analytics and solutions services. The company operates in the United States, Canada, and other countries.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.